Anti-Human CD3 x CD20 (Glofitamab) [Clone RG6026],Leinco,C1080

Glofitamab is a CD20xCD3 Bispecific T cell Engager (BiTE) antibody developed as a cancer immunotherapy that is engineered to have a novel 2:1 configuration of two anti-CD20 Fabs and one anti-CD3ɛ Fab 1,2 . One of the CD20 Fabs is fused in a “head-to-tail” fashion to the anti- CD3ɛ Fab via a flexible linker. Glofitamab simultaneously binds bivalently to CD20 on B cells and monovalently to CD3ɛ on T cells, leading to the formation of an immunological synapse between the CD20-expressing B cells and the CD3-expressing T cells 3 . As a result, T cell activation and proliferation is promoted and ultimately T cell mediated lysis of CD20-expressing B cells occurs. Additionally, Glofitamab treatment promotes the recruitment of peripheral blood T cells as well as a dose-dependent transient induction of proinflammatory cytokines, including interferon-γ, IL-6, IL-2, IL-8, IL-10, IL-15 and IL-17. Glofitamab also initiates antibody- dependent cell cytoxicity 3 and carries PG LALA mutations to abolish binding to Fcγ receptors and complement component C1q 1 , while maintaining neonatal Fc receptor (FcRn) binding 2 . CD20 is a nonglycosylated 33-37 kDa phosphoprotein member of the MS4A family 4,5 . The biological role of CD20 remains poorly understood; however, it is thought to be involved in calcium ion influx. CD20 has no natural ligand and is not immediately internalized upon antibody binding. Thus, mAbs directed against CD20 depend on the recruitment of a host response. CD3 is an invariant antigen of the T cell TCR (T cell receptor), which is responsible for recognizing peptides bound to MHC molecules. Glofitamab has been approved for the treatment of B cell non-Hodgkin lymphomas, including diffuse large B cell lymphoma 3 .